Get the Stockscreener App
1.905
1.87%
0.035
Lantern Pharma Inc stock is traded at $1.905, with a volume of 134.53K.
It is up +1.87% in the last 24 hours and down -30.73% over the past month.
Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.
See More
Previous Close:
$1.87
Open:
$1.86
24h Volume:
134.53K
Relative Volume:
0.82
Market Cap:
$24.35M
Revenue:
-
Net Income/Loss:
$-15.91M
P/E Ratio:
-1.3183
EPS:
-1.445
Net Cash Flow:
$-15.07M
1W Performance:
-7.97%
1M Performance:
-30.73%
6M Performance:
-32.45%
1Y Performance:
-54.64%
1-Day Range:
$1.83
$1.93
1-Week Range:
$1.81
$2.14
52-Week Range:
$1.11
$4.7034
Lantern Pharma Inc Stock (LTRN) Company Profile
Name
Lantern Pharma Inc
Sector
Industry
Phone
972-277-1136
Address
1920 MCKINNEY AVENUE, DALLAS, TX
Compare LTRN vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LTRN
Lantern Pharma Inc
|
1.905 | 29.28M | 0 | -15.91M | -15.07M | -1.445 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Lantern Pharma Inc Stock (LTRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-07-21 | Initiated | H.C. Wainwright | Buy |
Lantern Pharma Inc Stock (LTRN) Latest News
Lantern Pharma (LTRN) Q2 2026 Earnings Call Transcript - AOL.com
Lantern Pharma Inc (LTRN) (Q2 2026) Earnings Call Highlights: AI - GuruFocus
Lantern Pharma Inc (LTRN) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Lantern Pharma Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:LTRN) 2026-08-17 - Seeking Alpha
Lantern Pharma (LTRN) Slides 2.26% as Biotech Stock Approaches Critical $2.46 SupportKey Reversal Day - vinanet.vn
Lantern Pharma (LTRN) Updates Trial Design Amid Cash Raise; Mark - GuruFocus
Lantern Pharma (LTRN) Edges Up 0.76% to $2.65: Rangebound Trading Between Support and ResistanceBull Pennant - vinanet.vn
LTRN News | LANTERN PHARMA INC (NASDAQ:LTRN) - ChartMill
Form 8K Lantern Pharma Inc For: 14 August By Investing.com - Investing.com Nigeria
LTRN: Static price chart | Lantern Pharma Inc. | US51654W1018 - marketscreener.com
Lantern Pharma Reports 46.2% Wider Q2 2026 Loss at -$0.57/Share - AlphaStreet
Lantern Pharma Releases Q2 2026 Financial Results - AlphaStreet
Lantern Pharma (LTRN) Advances AI-Driven Oncology Pipeline Amid Valuation Challenges - GuruFocus
Lantern Q2 2026 slides: operating loss drops 25%, LP-300 data strengthens - Investing.com Canada
Lantern Pharma Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Earnings call transcript: Lantern Pharma posts q2 2026 loss miss as stock slips - Investing.com Nigeria
LTRN: AI-driven clinical pipeline and Open-Medicine AI spin-out drive growth amid reduced expenses - TradingView
LTRN: Open-Medicine AI spinout and clinical advances drove a leaner Q2 with reduced operating loss - TradingView
Lantern Pharma Q2 2026 Earnings Call Transcript - MarketBeat
BRIEF-Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - Dailyhunt
Q2 2026 Lantern Pharma Inc Earnings Call Transcript - GuruFocus
Lantern Pharma Q2 EPS of $(0.57) misses estimate by 50% - scanx.trade
Lantern Pharma Reports Second Quarter 2026 Financial Results And Provides Business Update - TradingView
Lantern Pharma Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Is Lantern Pharma Inc (LTRN) Facing Increased Losses After Q2 Ea - GuruFocus
Lantern Pharma Forms Open Medicine AI Subsidiary Business - tipranks.com
Lantern Pharma Q2 operating loss widens on warrant expenses tied to higher stock price - TradingView
Lantern Pharma Inc. Q2 2026: Net income $(7.07M), EPS $(0.57) — 10-Q Summary - TradingView
Lantern Pharma Reports $7.1 Million Q2 Net Loss as LP-184 Trial Clears - Quiver Quantitative
Lung cancer trial narrows focus after 8.9-month progression-free result - Stock Titan
Lantern Pharma (LTRN) Earnings Date and Reports 2026 $LTRN - MarketBeat
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Certain Common Stock of Lantern Pharma Inc. are subject to a Lock-Up Agreement Ending on 13-AUG-2026. - marketscreener.com
Lantern Pharma Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Lantern Pharma (LTRN.US) will release its earnings report before market open on August 14. - Moomoo
Empery Asset Management, LP Acquires 1.3 Million Shares of Lantern Pharma Inc (LTRN) - GuruFocus
Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET - Business Wire
LTRN Price History for Lantern Pharma Stock - Barchart.com
LTRN Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Lantern Pharma (LTRN): Empery Asset Management discloses 9.99% beneficial stake - Stock Titan
Lantern Pharma Spins Off Open-Medicine AI Platform - TipRanks
Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - BioSpace
Lantern Pharma (LTRN) Establishes Open-Medicine AI to Expand Mul - GuruFocus
Lantern Pharma establishes Open-Medicine AI to commercialize multi-agent AI co-scientist platform - TradingView
Lantern Pharma spins out AI platform into Open-Medicine AI - Investing.com
Lantern Pharma spins out AI platform into Open-Medicine AI By Investing.com - Investing.com Canada
Lantern Pharma’s bladder cancer trial cleared by EMA - Investing.com Nigeria
Lantern Pharma (LTRN) Gains EMA Approval for Phase 1b/2 Trial in Bladder Cancer - GuruFocus
Two Tumor Markers Will Guide Lantern Pharma's Bladder Cancer Trial - Stock Titan
Lantern Pharma (LTRN) Slides 6.8% as Stock Tests Key Support at $2.47Wyckoff Upthrust - vinanet.vn
LTRN|Lantern Pharma Inc|Price:2.890|Chg%:+0.140 - TradingKey
Lantern Pharma Inc Stock (LTRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lantern Pharma Inc Stock (LTRN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| KEYSER D JEFFREY | Director |
May 12 '26 |
Buy |
2.06 |
48,544 |
100,001 |
94,303 |
0.86%
0.31%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):